Resensitizing β‐Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment
Advanced Science · 2025
DOI: 10.1002/advs.202410781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Tingwang Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Shanghai Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Ton…. Hauptthemen laut MEDLINE: Osteomyelitis, Purines, Anti-Bacterial Agents, beta-Lactams. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Shanghai Pilot Program for Basic Research-Chinese Academy of Science, National Natural Science Foundation of China.
Abstract (Originalsprache)
Small colony variant (SCV) is strongly linked to antibiotic resistance and the persistence of osteomyelitis. However, the intrinsic phenotypic instability of SCV has hindered a thorough investigation of its pathogenic mechanisms. In this study, phenotypically stable SCV strains are successfully recovered from clinical specimens, characterized by elevated drug resistance and reduced immunogenicity. Multi‐omics analysis revealed that the acquired high drug resistance is associated with altered flux in the purine metabolism pathway, attributable to mutations in the hypoxanthine phosphoribosyltransferase ( hpt ) gene. Furthermore, this study innovatively discovered that lonidamine, an inhibitor of cellular energy metabolism, can effectively mitigate SCV resistance to β‐lactam antibiotics, thereby facilitating its eradication. The underlying mechanism involves the reprogramming of purine metabolism. Therefore, a co‐delivery system for lonidamine and oxacillin is constructed with amino‐modified dendritic mesoporous silica as a carrier, which showed high efficacy and safety in combating SCV both in vitro and in vivo experiments. Overall, this study elucidated the pathogenic mechanisms of a class of clinically isolated SCV isolates with hpt mutations and provided a paradigm for treating SCV‐associated osteomyelitis by reprogramming purine metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Shanghai Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, Ch…
- Department of Laboratory Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, China.
- Department of Orthopedic Surgery, Spine Lab, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
- Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
- Shanghai Institute of Ceramics Chinese Academy of Sciences, Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences, Shanghai, 200050, China.
- Department of Electrical and Electronic Engineering, The University of Hong Kong, Pokfulam Road, Hong Kong, 999077, China.
ORCID-Profile: Min Ge, Yunfeng Chen
Förderung
- National Key R&D Program of China
- Shanghai Pilot Program for Basic Research-Chinese Academy of Science
- National Natural Science Foundation of China
- Shanghai Shenkang Hospital Development Center
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- National Key Research and Development Program of China
Zitieren
APA
Shi, T., Wu, Q., Ruan, Z., Luo, Z., Wang, W., Guo, Z., Ma, Y., Wang, X., Chu, G., Lin, H., Ge, M., & Chen, Y. (2025). Resensitizing β‐Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment. Advanced Science. https://doi.org/10.1002/advs.202410781
Vancouver
Shi T, Wu Q, Ruan Z, Luo Z, Wang W, Guo Z, et al. Resensitizing β‐Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment. Advanced Science. 2025. doi:10.1002/advs.202410781
BibTeX
@article{Shi2025,
author = {Shi, Tingwang and Wu, Qiong and Ruan, Zesong and Luo, Zhiyuan and Wang, Wenbo and Guo, Zhao and Ma, Yihong and Wang, Xin and Chu, Guangyu and Lin, Han and Ge, Min and Chen, Yunfeng},
title = {Resensitizing β‐Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202410781}
}
EUVIMED